0001104659-21-007820.txt : 20210126 0001104659-21-007820.hdr.sgml : 20210126 20210126210021 ACCESSION NUMBER: 0001104659-21-007820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210122 FILED AS OF DATE: 20210126 DATE AS OF CHANGE: 20210126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coffin Robert CENTRAL INDEX KEY: 0001376492 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 21556463 MAIL ADDRESS: STREET 1: C/O BIOVEX GROUP, INC. STREET 2: 34 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 10801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 tm213368d7_4.xml OWNERSHIP DOCUMENT X0306 4 2021-01-22 0 0001737953 Replimune Group, Inc. REPL 0001376492 Coffin Robert C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK WOBURN MA 01801 1 1 0 0 President & Chief R&D Officer Common Stock 2021-01-22 4 S 0 30197 44.87 D 1773921 D Common Stock 2021-01-22 4 S 0 29803 43.99 D 1744118 D The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.38 to $45.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.41 to $44.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,744,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 483,771 of which are exercisable as of the date hereof. /s/ Jean Franchi, attorney-in-fact 2021-01-26